news

# Lilly discontinues development of evacetrapib due to insufficient efficacy

0
SHARES
Share via

Posted: 12 October 2015 |

Lilly has said that it will conclude studies of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease…

Lilly and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of evacetrapib due to insufficient efficacy.

Lilly has said that it will discontinue development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease and will now conclude other studies in the programme.

The independent data monitoring committee based its recommendation on data from periodic data reviews, which suggested there was a low probability the study would achieve its primary endpoint based on results to date. The study is not being stopped for safety findings.